Gilead says Q2 2026 revenue growth is driven by Biktarvy, Descovy and Yeztugo demand, pricing gains

Reuters2026/08/04 21:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gilead posted Q2 2026 revenue of $7.8 billion, driven by HIV growth, led by Biktarvy demand and pricing.
HIV sales rose 12% to $5.69 billion; Biktarvy increased 7% to $3.77 billion, supported by channel mix and inventory build.
PrEP sales more than doubled to $1.03 billion; Descovy for PrEP rose 60% to $801 million, Yeztugo reached $232 million.
Liver disease sales climbed 10% to $877 million on higher demand in PBC, HBV, HDV, partly offset by fewer HCV starts.
Full-year product sales guidance rose to $30.1 billion-$30.4 billion; HIV growth outlook increased to 9%-10%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Gilead says Q2 2026 revenue growth is driven by Biktarvy, Descovy and Yeztugo demand, pricing gains

You may also like

Crypto prices